First Roche, Then Bristol: Who’s Next?
This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.
This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.